Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713666 | 0.81 | TDP1 (0.63) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL1039253 | 0.81 | TDP1 (0.63) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL1306628 | 0.79 | TDP1 (0.59) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL6794361 | 0.78 | TDP1 (0.76) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL30564238 | 0.78 | TDP1 (0.76) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL6442808 | 0.78 | TDP1 (1.00) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL3966477 | 0.76 | TDP1 (0.73) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL9378705 | 0.76 | SMN1; SMN2 (0.55) | TDP1LMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL31462150 | 0.76 | SMN1; SMN2 (0.55) | TDP1LMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL19911333 | 0.76 | TNF (0.44) | TDP1CYP11B1CYP11B2TNFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119654318-A | Compounds and pharmaceutical compositions for degrading SWI/SNF-associated matrix-associated actin-dependent chromatin subfamily A modulators | 普莱克斯姆公司 | 2025-03-18 | — | — | CN | disclosed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-0320992-B1 | Triazolodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 1994-07-27 | — | — | EP | disclosed |
| EP-0214600-B1 | CEPHALOSPORIN DERIVATIVES | Otsuka Kagaku Kabushiki Kaisha (JP) | 1992-12-02 | — | — | EP | disclosed |
| US-4959361-A | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists | HOFFMANN-LA ROCHE INC. (US) | 1990-09-25 | — | — | US | disclosed |
| US-4906623-A | 3-Imidazolium cephalosporin derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0320992-A2 | Triazolodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-06-21 | — | — | EP | disclosed |
| EP-0214600-A2 | Cephalosporin derivatives | Otsuka Kagaku Kabushiki Kaisha (JP) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | TDP1 979/4885CYP11B1 640/4885CYP11B2 607/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | TDP1 934/4885CYP11B1 1952/4885CYP11B2 1938/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | TDP1 979/4885CYP11B1 640/4885CYP11B2 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.